Inflammation and altered drug clearance in cancer: Transcriptional repression of a human CYP3A4 transgene in tumor-bearing mice

Clinical Pharmacology and Therapeutics

Volumn 83, Issue 6, 2008, Pages 894-897

  Robertson, G R ^a   Liddle, C ^a   Clarke, S J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; ANTINEOPLASTIC AGENT; BLEOMYCIN; C REACTIVE PROTEIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450 3A4; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ERYTHROMYCIN; ETOPOSIDE; GEFITINIB; HYDROCORTISONE; IMATINIB; INTERLEUKIN 6; IRINOTECAN; MIDAZOLAM; MITOXANTRONE; NAVELBINE; OROSOMUCOID; PACLITAXEL; PREDNISOLONE; PREDNISONE; PREGNANE X RECEPTOR; TAMOXIFEN; TENIPOSIDE; TOPOTECAN; VINBLASTINE; VINCRISTINE; VINDESINE;

ADVANCED CANCER; ARTICLE; B CELL LYMPHOMA; BETA GALACTOSIDASE REPORTER GENE; BONE MARROW SUPPRESSION; BREATH ANALYSIS; CANCER PATIENT; CYTOCHROME P450 3A4 GENE; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; FEVER; GENE; GENE CONTROL; HUMAN; INFECTION; INFLAMMATION; LEUKOPENIA; NEOPLASM; NIGHT SWEAT; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; TUMOR MODEL; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYTOCHROME P-450 CYP3A; HUMANS; INFLAMMATION; METABOLIC CLEARANCE RATE; MICE; MICE, TRANSGENIC; NEOPLASMS; TRANSCRIPTION, GENETIC; TRANSGENES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 43949096582     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.55     Document Type: Article

References (24)

1. Gurney, H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J. Clin. Oncol. 14, 2590-2611 (1996).
2. Felici, A., Verweij, J. & Sparreboom, A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur. J. Cancer 38, 1677-1684 (2002).
3. Baker, S.D. et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin. Cancer Res. 10, 8341-8350 (2004).
4. Lepper, E.R. et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin. Cancer Res. 11, 7398-7404 (2005).
5. Henningsson, A. et al. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin. Cancer Res. 11, 8097-8104 (2005).
6. Marsh, S. et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer. Pharmacogenomics J. 7, 362-365 (2007).
7. Streetman, D.S., Bertino, J.S. Jr. & Nafziger, A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 10, 187-216 (2000).
8. Fuhr, U., Jetter, A. & Kirchheiner, J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin. Pharmacol. Ther. 81, 270-283 (2007).
9. Yamamoto, N., Tamura, T., Kamiya, Y., Sekine, I., Kunitoh, H. & Saijo, N. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol. J. Clin. Oncol. 18, 2301-2308 (2000).
10. Rivory, L.P. et al. Optimizing the erythromycin breath test for use in cancer patients. Clin. Cancer Res. 6, 3480-3485 (2000).
11. Rivory, L.P., Slaviero, K.A., Hoskins, J.M. & Clarke, S.J. The erythromycin breath test for the prediction of drug clearance. Clin. Pharmacokinet. 40, 151-158 (2001).
12. Charles, K.A. et al. Predicting the toxicity of weekly docetaxel in advanced cancer. Clin. Pharmacokinet. 45, 611-622 (2006).
13. Rivory, L.P., Slaviero, K.A. & Clarke, S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 87, 277-280 (2002).
14. Slaviero, K.A., Clarke, S.J. & Rivory, L.P. Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy. Lancet Oncol. 4, 224-232 (2003).
15. Aitken, A.E., Richardson, T.A. & Morgan, E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Ann. Rev. Pharmacol. Toxicol. 46, 123-149 (2006).
16. Teng, S. & Piquette-Miller, M. Regulation of transporters by nuclear hormone receptors: implications during inflammation. Mol. Pharm. 5, 67-76 (2008).
17. Petrovic, V., Teng, S. & Piquette-Miller, M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 7, 99-111 (2007).
18. Robertson, G.R. et al. Transgenic mouse models of human CYP3A4 gene regulation. Mol. Pharmacol. 64, 42-50 (2003).
19. Goodwin, B., Hodgson, E. & Liddle, C. The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol. 56, 1329-1339 (1999).
20. Goodwin, B., Hodgson, E., D'Costa, D.J., Robertson, G.R. & Liddle, C. Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor. Mol. Pharmacol. 62, 359-365 (2002).
21. Stedman, C., Robertson, G.R., Coulter, S. & Liddle, C. Feed-forward regulation of bile acid detoxification by CYP3A4: studies in humanized transgenic mice. J. Biol. Chem. 279, 11336-11343 (2004).
22. Charles, K.A. et al. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res. 12, 7492-7497 (2006).
23. Sharma, R. et al. Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br. J. Cancer 98, 91-97 (2008).
24. Jover, R., Bort, R., Gómez-Lechón, M.J. & Castell, J.V. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. FASEB J. 16, 1799-1801 (2002).